BPIFB4 and acute coronary syndrome: Thus, future efforts to underpin the role of LAV-BPIFB4 in megakaryopoiesis and in the immune regulatory action of the platelets may be useful for human applications to prevent or treat the thrombocytopenia that would otherwise occur in several disease conditions, including sepsis, acute coronary syndrome, and in immunothrombosis.